Agenus Stock Price, News & Analysis

Agenus (Nasdaq: AGEN) will host an End-of-Year 2025 Stakeholder Webcast on December 3, 2025 at 4:00 p.m. ET. The webcast features GI oncology experts and patient advocates discussing progress of the BOT/BAL program, emerging clinical insights, and the evolving colorectal cancer treatment landscape.

Speakers include Dr. Christopher Lieu, Dr. Jonathan Loree, and Dr. Benny Johnson; session moderated by Garo Armen, PhD, and ending with a live Q&A. Registration is required; a live webcast link is provided after registering and questions may be submitted in advance to ask@agenusbio.com. This is the third session in Agenus’ 2025 Stakeholder Briefing Webcast Series.

Agenus (Nasdaq: AGEN) appointed Dr. José Iglesias as Chief Medical Affairs Officer effective November 10, 2025 to lead global medical affairs for the BOT/BAL combination as it advances through the Phase 3 BATTMAN program.

Dr. Iglesias will oversee medical evidence generation, scientific exchange, and early-access frameworks, including France’s Autorisation d’Accès Compassionnel (AAC), where BOT/BAL has received AAC authorization with full government reimbursement and treatment has begun for eligible MSS colorectal cancer patients. Agenus plans named-patient and other early-access programs in additional geographies and emphasizes collecting robust real-world evidence.

Agenus (Nasdaq: AGEN) reported Q3 2025 results and a business update highlighting clinical and regulatory progress for botensilimab plus balstilimab (BOT/BAL).

Key items: France authorized reimbursed compassionate access for BOT/BAL in refractory MSS mCRC without active liver metastases; Phase 3 BATTMAN global registrational trial launching Q4 2025 across 100+ sites; updated survival data showing 42% two‑year OS in 123 MSS mCRC patients and 39% two‑year OS across >400 pan‑tumor patients; a ~$100.9M gain from MiNK deconsolidation and a $10M bridge ahead of an anticipated $91M Zydus closing.

Agenus (Nasdaq: AGEN) said it will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.

The company also plans a stakeholder briefing webcast in late November to provide a corporate and clinical development update; timing and access details will be announced in the coming weeks.

Agenus (Nasdaq: AGEN) reported updated clinical data for the botensilimab (BOT) plus balstilimab (BAL) combination from expansion cohorts of the Phase 1b C-800-01 study presented at ESMO 2025. Across 411 enrolled patients (339 evaluable), the pan-tumor dataset showed a 2-year overall survival (OS) of 39%, median OS of 17.2 months, and objective response rate (ORR) of 17%. Sixty-one percent received ≥3 prior lines of therapy. The combo was generally tolerable with reversible immune-related GI events and no treatment-related deaths. France granted compassionate access for BOT+BAL in refractory MSS mCRC.

Agenus (Nasdaq: AGEN) will host a virtual Stakeholder Briefing on Tuesday, October 21, 2025 at 4:00 p.m. ET to share post-ESMO clinical updates and global access progress for its immunotherapy combination botensilimab (BOT) and balstilimab (BAL).

Speakers include Michael S. Gordon, MD, discussing ESMO 2025 results from >400 patients treated with BOT/BAL across refractory solid tumors, and Alexander M.M. Eggermont, MD, PhD, on France’s AAC program and BOT/BAL inclusion. The session, moderated by Garo Armen, will end with live Q&A. No pre-registration is required and a webcast link is provided.

Agenus (NASDAQ: AGEN) has achieved a significant milestone as its investigational combination therapy botensilimab plus balstilimab (BOT/BAL) receives reimbursed compassionate access in France for treating refractory microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

The treatment will be available through France's Accès compassionnel (AAC) framework, with 100% coverage by Assurance Maladie for eligible patients. Clinical data shows promising results, including ~21-month median overall survival, ~42% 2-year survival, and ~20% objective response rate in expanded cohorts.

The AAC authorization enables hospital use with full reimbursement at the invoiced purchase price, outside the Diagnosis-related Group. EU/EEA patients may access the treatment in France under specific directives, while non-EU countries like Turkey can participate through treatment-abroad programs.

Agenus (NASDAQ:AGEN), an immuno-oncology company, will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York City.

The company's executives, Dr. Richard Goldberg (Chief Development Officer) and Dr. Robin Taylor (Chief Commercial Officer), will conduct a fireside chat on September 9, 2025, from 10:00-10:30 AM EST. They will discuss the BOT/BAL immunotherapy program, including updates on the pivotal Phase 3 BATTMAN trial in metastatic colorectal cancer, clinical data, partnerships, and upcoming milestones for H2 2025.

Agenus (Nasdaq: AGEN), a leader in immuno-oncology, has announced updated details for its virtual Stakeholder Briefing scheduled for August 27, 2025, at 4:00 p.m. ET. The webcast will feature a new virtual format and updated participation link, requiring no pre-registration.

The briefing will cover several key areas including strategic and financial overview, Zydus partnership updates, colorectal cancer (CRC) studies, BOT/BAL clinical updates, and Phase 3 BATTMAN study in metastatic CRC. Additionally, the session will spotlight MiNK Therapeutics, where Agenus holds a significant stake.

Distinguished speakers include CEO Garo H. Armen, Chief Development Officer Richard M. Goldberg, and other experts in GI oncology and cancer research. The event will conclude with a live Q&A session.